KR101177888B1 - Composition for Relieving and Preventing Hangover - Google Patents
Composition for Relieving and Preventing Hangover Download PDFInfo
- Publication number
- KR101177888B1 KR101177888B1 KR1020090011474A KR20090011474A KR101177888B1 KR 101177888 B1 KR101177888 B1 KR 101177888B1 KR 1020090011474 A KR1020090011474 A KR 1020090011474A KR 20090011474 A KR20090011474 A KR 20090011474A KR 101177888 B1 KR101177888 B1 KR 101177888B1
- Authority
- KR
- South Korea
- Prior art keywords
- vitamin
- weight
- acid
- hangover
- composition
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 59
- 206010019133 Hangover Diseases 0.000 title claims abstract description 42
- 239000000284 extract Substances 0.000 claims abstract description 33
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims abstract description 29
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims abstract description 28
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims abstract description 24
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 claims abstract description 24
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 claims abstract description 24
- 230000000694 effects Effects 0.000 claims abstract description 21
- 235000013305 food Nutrition 0.000 claims abstract description 14
- 239000001530 fumaric acid Substances 0.000 claims abstract description 14
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims abstract description 14
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 claims abstract description 12
- 239000004471 Glycine Substances 0.000 claims abstract description 12
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 claims abstract description 12
- 229930003270 Vitamin B Natural products 0.000 claims abstract description 12
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 claims abstract description 12
- 210000004185 liver Anatomy 0.000 claims abstract description 12
- 229960003080 taurine Drugs 0.000 claims abstract description 12
- 235000019156 vitamin B Nutrition 0.000 claims abstract description 12
- 239000011720 vitamin B Substances 0.000 claims abstract description 12
- 235000014852 L-arginine Nutrition 0.000 claims abstract description 11
- 229930064664 L-arginine Natural products 0.000 claims abstract description 11
- 229960002989 glutamic acid Drugs 0.000 claims abstract description 11
- 230000035622 drinking Effects 0.000 claims abstract description 9
- 238000011084 recovery Methods 0.000 claims abstract description 9
- YEFOAORQXAOVJQ-UHFFFAOYSA-N wuweizischun A Natural products C1C(C)C(C)(O)CC2=CC(OC)=C(OC)C(OC)=C2C2=C1C=C(OC)C(OC)=C2OC YEFOAORQXAOVJQ-UHFFFAOYSA-N 0.000 claims abstract description 9
- PXEDJBXQKAGXNJ-QTNFYWBSSA-L disodium L-glutamate Chemical compound [Na+].[Na+].[O-]C(=O)[C@@H](N)CCC([O-])=O PXEDJBXQKAGXNJ-QTNFYWBSSA-L 0.000 claims abstract description 7
- 230000002265 prevention Effects 0.000 claims abstract description 7
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 6
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 5
- 239000000843 powder Substances 0.000 claims description 12
- 239000002775 capsule Substances 0.000 claims description 9
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 claims description 8
- 235000013361 beverage Nutrition 0.000 claims description 7
- 239000003826 tablet Substances 0.000 claims description 7
- 239000007788 liquid Substances 0.000 claims description 6
- 239000002253 acid Substances 0.000 claims description 5
- 238000001784 detoxification Methods 0.000 claims description 5
- RBCOYOYDYNXAFA-UHFFFAOYSA-L (5-hydroxy-4,6-dimethylpyridin-3-yl)methyl phosphate Chemical compound CC1=NC=C(COP([O-])([O-])=O)C(C)=C1O RBCOYOYDYNXAFA-UHFFFAOYSA-L 0.000 claims description 4
- JZRWCGZRTZMZEH-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 claims description 4
- 102000007698 Alcohol dehydrogenase Human genes 0.000 claims description 3
- 108010021809 Alcohol dehydrogenase Proteins 0.000 claims description 3
- 239000008187 granular material Substances 0.000 claims description 2
- 239000006187 pill Substances 0.000 claims description 2
- 108010081577 aldehyde dehydrogenase (NAD(P)+) Proteins 0.000 claims 1
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 abstract description 30
- 210000004369 blood Anatomy 0.000 abstract description 27
- 239000008280 blood Substances 0.000 abstract description 27
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract description 25
- FEWJPZIEWOKRBE-JCYAYHJZSA-L L-tartrate(2-) Chemical compound [O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O FEWJPZIEWOKRBE-JCYAYHJZSA-L 0.000 abstract description 9
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 abstract description 8
- 208000024891 symptom Diseases 0.000 abstract description 7
- 239000004310 lactic acid Substances 0.000 abstract description 4
- 235000014655 lactic acid Nutrition 0.000 abstract description 4
- 229930195714 L-glutamate Natural products 0.000 abstract description 3
- 230000002829 reductive effect Effects 0.000 abstract description 3
- 230000028327 secretion Effects 0.000 abstract description 3
- 235000019441 ethanol Nutrition 0.000 description 24
- 235000013376 functional food Nutrition 0.000 description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- 206010016256 fatigue Diseases 0.000 description 9
- 239000000796 flavoring agent Substances 0.000 description 9
- 238000002360 preparation method Methods 0.000 description 9
- 240000006079 Schisandra chinensis Species 0.000 description 8
- 235000008422 Schisandra chinensis Nutrition 0.000 description 8
- 235000019634 flavors Nutrition 0.000 description 8
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 8
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- 239000001384 succinic acid Substances 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 235000014443 Pyrus communis Nutrition 0.000 description 5
- 240000001987 Pyrus communis Species 0.000 description 5
- 240000008866 Ziziphus nummularia Species 0.000 description 5
- 235000013334 alcoholic beverage Nutrition 0.000 description 5
- 230000036541 health Effects 0.000 description 5
- 239000004615 ingredient Substances 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 108010082126 Alanine transaminase Proteins 0.000 description 4
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 4
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 4
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- 229930091371 Fructose Natural products 0.000 description 4
- 239000005715 Fructose Substances 0.000 description 4
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 4
- 229930003451 Vitamin B1 Natural products 0.000 description 4
- 229930003471 Vitamin B2 Natural products 0.000 description 4
- 239000001913 cellulose Substances 0.000 description 4
- 235000010980 cellulose Nutrition 0.000 description 4
- 229920002678 cellulose Polymers 0.000 description 4
- 235000012907 honey Nutrition 0.000 description 4
- 230000003647 oxidation Effects 0.000 description 4
- 238000007254 oxidation reaction Methods 0.000 description 4
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 4
- 229960002477 riboflavin Drugs 0.000 description 4
- 235000013616 tea Nutrition 0.000 description 4
- 229960003495 thiamine Drugs 0.000 description 4
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 4
- 230000004102 tricarboxylic acid cycle Effects 0.000 description 4
- 235000010374 vitamin B1 Nutrition 0.000 description 4
- 239000011691 vitamin B1 Substances 0.000 description 4
- 235000019164 vitamin B2 Nutrition 0.000 description 4
- 239000011716 vitamin B2 Substances 0.000 description 4
- 239000011726 vitamin B6 Substances 0.000 description 4
- 235000019158 vitamin B6 Nutrition 0.000 description 4
- 229940011671 vitamin b6 Drugs 0.000 description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 3
- 235000002789 Panax ginseng Nutrition 0.000 description 3
- 244000269722 Thea sinensis Species 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 239000008369 fruit flavor Substances 0.000 description 3
- 239000000543 intermediate Substances 0.000 description 3
- 239000001726 jatropha manihot extract Substances 0.000 description 3
- 229940069445 licorice extract Drugs 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000008213 purified water Substances 0.000 description 3
- 229940106668 yucca extract Drugs 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 2
- PZNPLUBHRSSFHT-RRHRGVEJSA-N 1-hexadecanoyl-2-octadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[C@@H](COP([O-])(=O)OCC[N+](C)(C)C)COC(=O)CCCCCCCCCCCCCCC PZNPLUBHRSSFHT-RRHRGVEJSA-N 0.000 description 2
- 206010000060 Abdominal distension Diseases 0.000 description 2
- 102000005369 Aldehyde Dehydrogenase Human genes 0.000 description 2
- 108020002663 Aldehyde Dehydrogenase Proteins 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- 239000001653 FEMA 3120 Substances 0.000 description 2
- 240000004670 Glycyrrhiza echinata Species 0.000 description 2
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 description 2
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 description 2
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 2
- 235000004552 Yucca aloifolia Nutrition 0.000 description 2
- 235000012044 Yucca brevifolia Nutrition 0.000 description 2
- 235000017049 Yucca glauca Nutrition 0.000 description 2
- 240000005780 Yucca gloriosa Species 0.000 description 2
- 238000011953 bioanalysis Methods 0.000 description 2
- 208000024330 bloating Diseases 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 231100000517 death Toxicity 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000007865 diluting Methods 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 235000019197 fats Nutrition 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 235000013402 health food Nutrition 0.000 description 2
- 239000012676 herbal extract Substances 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
- 229940010454 licorice Drugs 0.000 description 2
- 238000007449 liver function test Methods 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000000419 plant extract Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000008347 soybean phospholipid Substances 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 239000011975 tartaric acid Substances 0.000 description 2
- 235000002906 tartaric acid Nutrition 0.000 description 2
- 235000019640 taste Nutrition 0.000 description 2
- 230000035922 thirst Effects 0.000 description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- STGNLGBPLOVYMA-MAZDBSFSSA-N (E)-but-2-enedioic acid Chemical compound OC(=O)\C=C\C(O)=O.OC(=O)\C=C\C(O)=O STGNLGBPLOVYMA-MAZDBSFSSA-N 0.000 description 1
- FALRKNHUBBKYCC-UHFFFAOYSA-N 2-(chloromethyl)pyridine-3-carbonitrile Chemical compound ClCC1=NC=CC=C1C#N FALRKNHUBBKYCC-UHFFFAOYSA-N 0.000 description 1
- KPGXRSRHYNQIFN-UHFFFAOYSA-N 2-oxoglutaric acid Chemical compound OC(=O)CCC(=O)C(O)=O KPGXRSRHYNQIFN-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 208000000044 Amnesia Diseases 0.000 description 1
- 229920000856 Amylose Polymers 0.000 description 1
- 208000000412 Avitaminosis Diseases 0.000 description 1
- 206010048909 Boredom Diseases 0.000 description 1
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 208000007882 Gastritis Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010021135 Hypovitaminosis Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 208000026139 Memory disease Diseases 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 240000008790 Musa x paradisiaca Species 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- 206010028817 Nausea and vomiting symptoms Diseases 0.000 description 1
- SXFBQAMLJMDXOD-ZVGUSBNCSA-N OC(=O)C(O)C(O)C(O)=O.OC(=O)[C@H](O)[C@@H](O)C(O)=O Chemical compound OC(=O)C(O)C(O)C(O)=O.OC(=O)[C@H](O)[C@@H](O)C(O)=O SXFBQAMLJMDXOD-ZVGUSBNCSA-N 0.000 description 1
- 206010030216 Oesophagitis Diseases 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- 244000046052 Phaseolus vulgaris Species 0.000 description 1
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- 240000006394 Sorghum bicolor Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 240000004584 Tamarindus indica Species 0.000 description 1
- 235000004298 Tamarindus indica Nutrition 0.000 description 1
- WBWWGRHZICKQGZ-UHFFFAOYSA-N Taurocholic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(=O)NCCS(O)(=O)=O)C)C1(C)C(O)C2 WBWWGRHZICKQGZ-UHFFFAOYSA-N 0.000 description 1
- 241000219094 Vitaceae Species 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 206010000059 abdominal discomfort Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- IKHGUXGNUITLKF-XPULMUKRSA-N acetaldehyde Chemical compound [14CH]([14CH3])=O IKHGUXGNUITLKF-XPULMUKRSA-N 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 230000037354 amino acid metabolism Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000000954 anitussive effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 229940124584 antitussives Drugs 0.000 description 1
- 235000021015 bananas Nutrition 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000003613 bile acid Substances 0.000 description 1
- 230000010234 biliary secretion Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 229960001714 calcium phosphate Drugs 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 229960003340 calcium silicate Drugs 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 150000001991 dicarboxylic acids Chemical class 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- PCHPORCSPXIHLZ-UHFFFAOYSA-N diphenhydramine hydrochloride Chemical compound [Cl-].C=1C=CC=CC=1C(OCC[NH+](C)C)C1=CC=CC=C1 PCHPORCSPXIHLZ-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 239000007938 effervescent tablet Substances 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 208000006881 esophagitis Diseases 0.000 description 1
- 239000003172 expectorant agent Substances 0.000 description 1
- 230000003419 expectorant effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 239000005417 food ingredient Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 210000004051 gastric juice Anatomy 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229940014259 gelatin Drugs 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 229940049906 glutamate Drugs 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 235000021021 grapes Nutrition 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 235000001497 healthy food Nutrition 0.000 description 1
- 230000010247 heart contraction Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- 230000002608 insulinlike Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 230000006984 memory degeneration Effects 0.000 description 1
- 208000023060 memory loss Diseases 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 239000005445 natural material Substances 0.000 description 1
- 230000009965 odorless effect Effects 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 229940055726 pantothenic acid Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 238000009928 pasteurization Methods 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 235000021018 plums Nutrition 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000009993 protective function Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 235000019643 salty taste Nutrition 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 235000019614 sour taste Nutrition 0.000 description 1
- 235000013322 soy milk Nutrition 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 235000019654 spicy taste Nutrition 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000001256 steam distillation Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000000859 sublimation Methods 0.000 description 1
- 230000008022 sublimation Effects 0.000 description 1
- 229940014800 succinic anhydride Drugs 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 210000000225 synapse Anatomy 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- WBWWGRHZICKQGZ-GIHLXUJPSA-N taurocholic acid Chemical compound C([C@@H]1C[C@H]2O)[C@@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@@H]([C@@H](CCC(=O)NCCS(O)(=O)=O)C)[C@@]2(C)[C@H](O)C1 WBWWGRHZICKQGZ-GIHLXUJPSA-N 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 208000030401 vitamin deficiency disease Diseases 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/38—Other non-alcoholic beverages
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/52—Adding ingredients
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
- A23L33/12—Fatty acids or derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23P—SHAPING OR WORKING OF FOODSTUFFS, NOT FULLY COVERED BY A SINGLE OTHER SUBCLASS
- A23P10/00—Shaping or working of foodstuffs characterised by the products
- A23P10/20—Agglomerating; Granulating; Tabletting
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23P—SHAPING OR WORKING OF FOODSTUFFS, NOT FULLY COVERED BY A SINGLE OTHER SUBCLASS
- A23P10/00—Shaping or working of foodstuffs characterised by the products
- A23P10/30—Encapsulation of particles, e.g. foodstuff additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23P—SHAPING OR WORKING OF FOODSTUFFS, NOT FULLY COVERED BY A SINGLE OTHER SUBCLASS
- A23P10/00—Shaping or working of foodstuffs characterised by the products
- A23P10/40—Shaping or working of foodstuffs characterised by the products free-flowing powder or instant powder, i.e. powder which is reconstituted rapidly when liquid is added
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/334—Foods, ingredients or supplements having a functional effect on health treating the effects of consuming alcohol, narcotics or other addictive behavior, e.g. treating hangover or reducing blood alcohol levels
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/02—Acid
- A23V2250/036—Fumaric acid
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/02—Acid
- A23V2250/056—Tartaric acid
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/02—Acid
- A23V2250/06—Amino acid
- A23V2250/0606—Arginine
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/02—Acid
- A23V2250/06—Amino acid
- A23V2250/0612—Carnitine
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/02—Acid
- A23V2250/06—Amino acid
- A23V2250/0622—Glycine
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/02—Acid
- A23V2250/06—Amino acid
- A23V2250/0644—Taurine
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/70—Vitamins
- A23V2250/704—Vitamin B
- A23V2250/7042—Vitamin B1
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/70—Vitamins
- A23V2250/704—Vitamin B
- A23V2250/7044—Vitamin B2
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/70—Vitamins
- A23V2250/704—Vitamin B
- A23V2250/7052—Vitamin B6
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Mycology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Botany (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
본 발명은 식품 및 의약 조성물에 관한 것으로, 더욱 구체적으로는 호박산, 푸마르산, L-글루타민산 또는 L-글루타민산나트륨, 비타민 B군, L-주석산, 타우린, L-아르기닌, L-카르니틴, 글리신 및 오미자 추출물을 포함하는 것을 특징으로 하는 음주로 인한 숙취 증상의 예방, 해소용 조성물에 관한 것이다. 본 발명의 조성물은 임상실험 결과 혈중 알코올 농도와 아세트알데히드 농도를 격감시키는 것으로 나타나 우수한 숙취 증상 예방 및 숙취해소 효능을 발휘할 뿐만 아니라, 음주로 인해 유발되는 간수치 증대를 억제하므로 간을 해독, 보호하는 효과도 갖는다. 또한, 상기 숙취해소의 효과와 더불어 젖산의 분비를 감소시키므로 피로 회복의 효과도 갖는다.The present invention relates to food and pharmaceutical compositions, more specifically succinic acid, fumaric acid, L- glutamic acid or sodium L- glutamate, vitamin B group, L-tartrate, taurine, L-arginine, L-carnitine, glycine and Schizandra extract It relates to the prevention, remedy composition for the hangover symptoms due to drinking, characterized in that it comprises a. The composition of the present invention has been shown to reduce the blood alcohol and acetaldehyde concentration in clinical trials, not only to exhibit excellent hangover prevention and hangover efficacy, but also to detoxify and protect the liver by inhibiting the increase in liver values caused by drinking. Also have. In addition, since the secretion of lactic acid is reduced along with the effect of the hangover, it also has the effect of fatigue recovery.
숙취해소, 호박산, 푸마르산, L-글루타민산 또는 L-글루타민산나트륨, 비타민 B군, L-주석산 Hangover Relief, Succinic Acid, Fumaric Acid, L-Glutamic Acid or L-Glutamate, Vitamin B Group, L-Tartrate
Description
본 발명은 식품 및 의약 조성물에 관한 것으로, 더욱 구체적으로는 호박산, 푸마르산, L-글루타민산 또는 L-글루타민산나트륨, 비타민 B군, L-주석산, 타우린, L-아르기닌, L-카르니틴, 글리신 및 오미자 추출물을 포함하는 것을 특징으로 하는 음주로 인한 숙취 증상의 예방, 해소용 조성물에 관한 것이다.The present invention relates to food and pharmaceutical compositions, more specifically succinic acid, fumaric acid, L- glutamic acid or sodium L- glutamate, vitamin B group, L-tartrate, taurine, L-arginine, L-carnitine, glycine and Schizandra extract It relates to the prevention, remedy composition for the hangover symptoms due to drinking, characterized in that it comprises a.
한국의 알코올 소비는 세계 최고의 수준이며, 간암이나 간경변으로 인한 사망이 한국인의 주요 사망원인이 되는 등 음주로 인한 사회경제적 및 보건학적 폐해는 엄청나며 이는 증가 추세에 있다. Korea's alcohol consumption is among the highest in the world, and the socioeconomic and health consequences of drinking alcohol are enormous and increasing, with deaths from liver cancer and cirrhosis becoming the leading cause of death for Koreans.
과다한 알코올 섭취는 갈증, 피로감/졸음, 두통/어지러움, 오심/구토, 무력감, 복부팽만감/위장관 불쾌감 등의 숙취현상(hangover)을 유발하며, 만성적으로는 간질환, 위염, 췌장염, 고혈압, 중풍, 식도염, 당뇨병 그리고 심장병 등 많은 질환을 일으키는 것으로 보고되고 있다. Excessive alcohol consumption can cause hangovers such as thirst, fatigue / drowsiness, headache / dizziness, nausea / vomiting, helplessness, bloating / gastrointestinal discomfort. Chronic liver disease, gastritis, pancreatitis, high blood pressure, stroke, It is reported to cause many diseases such as esophagitis, diabetes and heart disease.
정상적인 상태에서 알코올을 섭취할 경우 위장 또는 소장에서 흡수되어 혈관으로 들어가 간으로 옮겨지게 된다. 알코올은 알코올탈수소효소(Alcohol dehydrogenase, ADH)에 의해 아세트알데하이드(Acetaldehyde)로 전환되고, 이는 알데하이드 탈수소효소(Aldehyde dehydrogenase, ALDH)의 작용에 의해 아세테이트(Acetate)로 전환되어 순환계를 통해 간세포 밖으로 배설되어진다. If you consume alcohol in the normal state, it is absorbed by the stomach or small intestine, enters the blood vessels, and moves to the liver. Alcohol is converted to acetaldehyde by alcohol dehydrogenase (ADH), which is converted to acetate by the action of aldehyde dehydrogenase (ALDH) and excreted out of the liver cells through the circulation. Lose.
숙취 현상은 체내에 축적된 알코올(Alcohol) 및 에탄올의 최초 대사산물인 아세트알데하이드의 작용에 의해 발생하는 것으로 알려져 있다(Swift R et al., Alcohol Health Res World. 1998;22(1):54-60).Hangover is known to be caused by the action of acetaldehyde, the first metabolite of alcohol and alcohol (Scoft R et al ., Alcohol Health Res World. 1998; 22 (1): 54-). 60).
종래 이와 같은 숙취를 해소하기 위해서 콩나물, 북어 등을 이용한 음식물이 이용되어 왔으며 최근에는 숙취해소를 위한 많은 기능성 음료 또는 조성물들이 시판되고 있다.Conventionally, foods using bean sprouts, northern fish, etc. have been used to relieve such hangovers. Recently, many functional drinks or compositions for hangover relief have been marketed.
이들 종래 기술에 관련하여, 대한민국 공개특허 공보 제2005-0013073호에는 비타민과 허브추출물 분말을 포함하는 발포정의 제조방법이 개시되어 있고, 동 공개특허 공보 제2006-0117645호에는 천년초 추출액 및 엑스의 제조방법이 개시된 바 있으며, 대한민국 등록 특허 공보 제10-0372561호에는 천연 생약제 추출물을 포함하는 숙취해소용 조성물 및 이를 유효 성분으로 함유하는 건강보조식품이 개시되어 있는 등 다양한 천연소재 추출물에 의한 숙취해소제 특허들이 제안되어 있다.In relation to these prior arts, Korean Unexamined Patent Publication No. 2005-0013073 discloses a method for producing effervescent tablets containing vitamins and herbal extract powders, and Korean Patent Publication No. 2006-0117645 discloses preparation of extracts and extracts of cheonnyeoncho. The method has been disclosed, and the Republic of Korea Patent Publication No. 10-0372561 discloses hangover relief composition comprising a natural herbal extracts and health supplements containing the same as an active ingredient is disclosed hangover by various natural material extracts Patents have been proposed.
그러나, 위와 같은 숙취해소를 위한 다양한 노력에도 불구하고, 혈중 알코올 농도와 아세트알데히드 농도를 격감시켜, 간에서의 알코올 분해 효율이 더욱 증진된 기능성 조성물에 대한 요구가 여전히 있다.However, despite various efforts to relieve hangovers above, there is still a need for functional compositions in which blood alcohol and acetaldehyde levels are reduced, thereby further enhancing alcohol degradation efficiency in the liver.
본 발명자들은 인체에 우수한 숙취해소 및 예방 기능을 가지는 숙취해소용 조성물을 개발하기 위하여 연구를 거듭하던 중, 후술하는 바의 호박산, 푸마르산, L-글루타민산 또는 L-글루타민산나트륨, 비타민 B군, L-주석산, 타우린, L-아르기닌, L-카르니틴, 글리신 및 오미자 추출물을 함유한 조성물이 뛰어난 숙취 해소 효과를 나타내어 이것이 기능성 식품 및 의약으로 효율적으로 이용될 수 있음을 확인하고 본 발명을 완성하기에 이르렀다.The inventors of the present invention during the development of a hangover relief composition having excellent hangover relief and prevention function to the human body, succinic acid, fumaric acid, L- glutamic acid or L- glutamate, sodium vitamin B group, L- The composition containing tartaric acid, taurine, L-arginine, L-carnitine, glycine, and Schisandra chinensis extract exhibited excellent hangover-relieving effect, confirming that it can be efficiently used as a functional food and medicine, and completed the present invention.
따라서, 본 발명의 목적은 상술한 바와 같은 종래의 문제점을 해결하고, 음주로 인한 숙취증상을 효과적으로 예방하거나 숙취증상을 신속히 해소할 수 있는 의약 및 기능성 식품 조성물을 제공하는데 있다.Accordingly, an object of the present invention is to solve the conventional problems as described above, and to provide a medicinal and functional food composition that can effectively prevent the hangover symptoms due to drinking or to quickly resolve the hangover symptoms.
본 발명의 다른 목적은 간수치 증대를 억제하여 해독 작용 및 간을 보호하는 효과와 피로회복 효과를 갖는 조성물을 제공하는 데 있다.Another object of the present invention is to provide a composition having an effect of preventing detoxification, protecting the liver, and a fatigue recovery effect by inhibiting increase in liver values.
본 발명의 추가의 목적은 일반 소비자가 기호 또는 기능성 식품으로 이용할 수 있는 식품 조성물을 제공하는 데 있다.A further object of the present invention is to provide a food composition which can be used by consumers as a favorite or functional food.
본 발명의 조성물은 혈중 알코올 및 아세트알데히드 농도를 격감시키는 것으로 나타나 우수한 숙취 증상의 예방 및 숙취 해소의 효능을 발휘할 뿐만 아니라, 음주로 인해 유발되는 간수치 증대를 억제하므로 간을 해독, 보호하는 효과도 갖는다. 또한, 상기 숙취해소의 효과와 더불어 젖산의 분비를 감소시키므로 피로 회복의 효과도 갖는다. The composition of the present invention has been shown to significantly reduce the concentration of alcohol and acetaldehyde in the blood, thereby exerting the effect of preventing the hangover and preventing hangover, as well as inhibiting the increase in liver values caused by drinking, and thus detoxifying and protecting the liver. . In addition, since the release of lactic acid is reduced in addition to the effect of the hangover, it also has the effect of fatigue recovery.
본 발명은, 일면에 있어서, 호박산, 푸마르산, L-글루타민산 또는 L-글루타민산나트륨, 비타민 B군, L-주석산, 타우린, L-아르기닌, L-카르니틴, 글리신 및 오미자 추출물을 포함하는 것을 특징으로 하는 음주로 인한 숙취 증상의 예방 및 숙취해소용 조성물을 제공한다.The present invention, in one aspect, succinic acid, fumaric acid, L- glutamic acid or L- glutamate, sodium vitamin B group, L-tin acid, taurine, L- arginine, L- carnitine, glycine and Schizandra extract, characterized in that it comprises an extract Provided is a composition for preventing and preventing hangover symptoms caused by drinking.
본 발명은, 추가의 일면에 있어서, 상기 조성물에 더하여 액상 과당, 벌꿀, 황금 추출액, 유카 추출액, 배 추출액, 대추 추출액, 갈근 추출액, 감초 추출액, 매실 추출액, 홍삼향, 쌍화차향, 허브향, 및 과일향으로 이루어진 군 중에서 선택된 하나 이상의 성분을 포함하는 숙취 예방 및 숙취해소용 기능성 조성물을 제공한다.In still another aspect, the present invention provides liquid fructose, honey, golden extract, yucca extract, pear extract, jujube extract, brown root extract, licorice extract, plum extract, red ginseng flavor, biscented tea, herbal flavor, It provides a hangover prevention and hangover functional composition comprising at least one component selected from the group consisting of fruit flavor.
본 명세서에서 용어 "숙취(Hangover)"는 알코올 섭취 후에 나타나는 부작용, 즉 갈증, 전신권태, 피로감, 기억상실, 복부팽만감, 소화 불량, 구토, 설사, 비타민 결핍 등과 같이 섭취한 알코올 및 이의 대사물 알데하이드에 의해 유도되는 여러 가지 부작용을 의미한다. As used herein, the term "hang" refers to side effects that occur after alcohol consumption, such as thirst, systemic boredom, fatigue, memory loss, bloating, indigestion, vomiting, diarrhea, vitamin deficiency, and the like and their metabolite aldehydes. Means a number of side effects induced by.
이하, 본 발명을 더욱 상세하게 설명하기로 한다.Hereinafter, the present invention will be described in more detail.
본 발명의 조성물에 사용된 성분 중, 호박산은 숙신산(succinic acid)으로도 불리우며, 천연으로는 호박 속에 그 유도체가 함유되어 있으며, 이 밖에 테레빈유, 지의류, 균류 등에도 분포하고 알코올 발효시에도 소량 생성되며 청주 속에도 함유되어 있다. 무색무취이며 특이한 신맛을 지닌다. 열수(熱水), 알코올, 아세톤에 녹으나 에테르, 냉수에는 녹지 않는다. 끓는점까지 가열하면 한 분자의 물을 잃고 호박산무수물이 된다. 생체 내에서는 시트르산회로 등 여러 가지 대사과정의 중간물질로서 중요한 역할을 하고 있다. 호박산은 NADN-디하이드로게나이즈와는 독립적으로 아세트알데히드에 작용하여 아세트알데히드가 저산소증(Hypoxia)을 일으키지 못하도록 한다.Among the components used in the composition of the present invention, succinic acid is also referred to as succinic acid, and its derivative is naturally contained in amber, and is also distributed in terebin oil, lichens, fungi, etc. Produced and contained in sake. It is colorless and odorless and has an unusual sour taste. Soluble in hot water, alcohol, acetone, but insoluble in ether and cold water. Heating to the boiling point loses one molecule of water and turns into succinic anhydride. In vivo, it plays an important role as an intermediate of various metabolic processes such as the citric acid cycle. Succinic acid acts on acetaldehyde independently of NADN-dehydrogenase, preventing acetaldehyde from causing hypoxia.
상기 푸마르산(Fumaric Acid)은 불포화 디카르복시산의 일종으로 화학식은 C4H4O4이며, 녹는점 300～302℃(밀폐된 용기)의 특이한 신맛이 나는 바늘모양 결정으로, 약 200℃에서 승화한다. 에틸알코올에 녹으며, 물, 에테르, 아세톤에 잘 녹지 않는다. 생화학적으로 TCA 회로 중간생성물의 하나로 숙신산의 산화에 의해 만들어진다. 아미노산 대사에 있어서는 티로신과 페닐알라닌의 일부가 푸마르산을 거쳐 TCA회로에 들어간다. 또한 TCA회로의 다른 중간생성물과 함께 포스포에글피루브산을 거쳐 당을 생성하는 데도 이용된다.The fumaric acid (Fumaric Acid) is a kind of unsaturated dicarboxylic acid, the formula is C 4 H 4 O 4 , a unique sour needle crystal of melting point 300 ~ 302 ℃ (closed container), sublimation at about 200 ℃ . Soluble in ethyl alcohol, insoluble in water, ether and acetone. Biochemically produced by oxidation of succinic acid as one of the TCA cycle intermediates. In amino acid metabolism, some of tyrosine and phenylalanine enter the TCA cycle via fumaric acid. It is also used to produce sugars via phosphoeglypyruvic acid along with other intermediates of the TCA cycle.
상기 L-글루타민산(L-Glutamate), 또는 L-글루타민산나트륨(Monosodium L-Glutamate)은 아미노산의 주성분으로서 상기 분해반응식에 첨가되어 아세트알데히드의 무독성화에 핵심적 역할을 하는 미토콘드리아의 Cytosolic Malate-Aspartate의 속도를 높이며, 상기 호박산의 산화과정 속도도 촉진하게 된다. 또한 상기 L-글루타민은 크랩스 회로에서 빠른 산화과정을 거치는 동안 α-Ketoglutarate로 변형되며 최종적으로 뇌에 있어서 GAMC 시냅스와 글루타메이트(Glutamate)에 긍정적인 영향을 미쳐 알콜의 무독화를 촉진시킴으로써 알코올이 뇌에 미치는 악영향을 차단하는 기능을 한다.L-Glutamate, or L-Glutamate, is the main component of amino acids, and is added to the decomposition scheme to play a key role in the detoxification of acetaldehyde. To increase the speed of oxidation of the succinic acid. In addition, L-glutamine is transformed into α-Ketoglutarate during the rapid oxidation process in the Crab's circuit and finally has a positive effect on GAMC synapses and glutamate in the brain, promoting alcohol detoxification, It is a function to block adverse effects on the product.
상기 비타민 B는 일명 면역비타민으로 불리며, 비타민 B가 부족하면 흉선이 점점 축소되고 T-임파구의 생산도 감소되는 것으로 알려져 있다. 비타민 B에는 B1, B2, B3, B6, 판토텐산, 엽산, 비오틴, 콜린, 이노시톨 등 10여 종이 있으며, 본 발명에서는 특정의 것에 제한되지 않고 사용될 수 있으나, 특히 비타민 B1, 비타민 B2, 비타민 B6 또는 이들의 혼합물이 바람직하다.The vitamin B is known as immunovitamin, and it is known that the deficiency of vitamin B gradually reduces the thymus and reduces the production of T-lymphocytes. Vitamin B has about 10 species such as B 1 , B 2 , B 3 , B 6 , pantothenic acid, folic acid, biotin, choline, inositol, etc., but may be used without particular limitation in the present invention, in particular, vitamin B 1 , vitamin B 2 , vitamin B 6 or mixtures thereof are preferred.
L-주석산(타르타르산)은 흰색 결정을 지닌 유기산의 일종이다. 주석산은 포도, 바나나, 타마린드와 같은 많은 식물에서 존재하며, 와인에서 발견되는 주요한 산의 일종이다. 신맛을 가하기 위해 식품에 첨가되기도 하며, 산화방지제로서 사용되기도 한다.L-Tartaric acid (tartaric acid) is a type of organic acid with white crystals. Tartaric acid is present in many plants, such as grapes, bananas, and tamarinds, and is a major acid found in wine. It can be added to foods to add sourness, or used as an antioxidant.
상기 본 발명의 숙취해소용 조성물은 타우린, L-아르기닌, L-카르니틴, 글리신, 오미자 추출물, 액상과당, 벌꿀, 황금 추출액, 유카 추출액, 배 추출액, 대추 추출액, 갈근 추출액, 감초 추출액, 매실 추출액, 홍삼향, 쌍화차향, 허브향, 및 과일향으로 이루어진 군 중에서 선택된 하나 이상의 성분을 포함할 수 있다.The hangover composition of the present invention is taurine, L-arginine, L-carnitine, glycine, Schisandra extract, liquid fructose, honey, golden extract, yucca extract, pear extract, jujube extract, root extract, licorice extract, plum extract, It may include one or more components selected from the group consisting of red ginseng flavor, scented tea flavor, herbal flavor, and fruit flavor.
본 발명의 조성물에 있어서 타우린은 타우로콜산(taurocholic acid)과 같은 담즙산을 만들어 지방의 소화 흡수에 관여하며, 체내에서 간질발작을 억제하는 기능이 있고, 세포막의 보호기능이 있으며, 혈구와 폐조직의 산화를 방지하는 기능이 있다. 또한 중추신경계에 작용하고, 혈소판의 응집과 심장수축에 작용하며, 해독작용과 인슐린 유사기능도 보이고 있다. In the composition of the present invention, taurine is involved in the digestion and absorption of fat by making bile acids such as taurocholic acid, has the function of inhibiting epileptic seizures in the body, has a protective function of cell membranes, blood cells and lung tissue Has the function of preventing oxidation. It also acts on the central nervous system, on platelet aggregation and heart contraction, and also has detoxification and insulin-like functions.
또한, 오미자는 혈압강하 및 진해 거담작용을 갖고 있어서 한약재로 널리 이용되고 있을 뿐 아니라 위액 분비의 조절 및 담즙분비 촉진작용을 갖고 있어서 건 강 식품의 성분으로 널리 이용되고 있다. 특히 오미자는 단맛, 쓴맛, 신맛, 매운맛, 짠맛 등이 복합된 특이한 맛을 갖고 있으며 고유의 특이한 향을 나타내므로 다류와 주정 음료의 원료로도 이용되고 있다. In addition, Schisandra chinensis has a blood pressure lowering and antitussive expectorant action, which is not only widely used as a herbal medicine but also has a regulation of gastric juice secretion and biliary secretion, and thus is widely used as a component of healthy foods. In particular, Schisandra chinensis has a unique taste that combines sweetness, bitterness, sourness, spicy taste, salty taste, etc., and it is also used as a raw material for teas and spirit drinks.
상기 오미자, 황금, 유카, 배, 대추, 갈근, 감초, 매실 등의 추출물은 물과 각각의 재료를 용기에 넣고 물의 중량을 기준으로 1~5중량부로 혼합하여 고압멸균솥에 넣고 2~5 시간 동안 추출하여 여과하여 농축한 액을 재료로 사용하거나 분말 건조화 하여 분말상태로 사용한다. 별법으로, 상기 추출물들은 각 재료를 분쇄한 후에 물 또는 알코올로 추출할 수 있다. 또한 수증기 증류하여 추출하는 것도 바람직한 결과를 초래할 수 있다.The extract of Schisandra chinensis, golden, yucca, pear, jujube, brown root, licorice, plum, etc., put water and each material in a container and mix in 1 to 5 parts by weight based on the weight of water and put into a autoclave for 2 to 5 hours Extracted, filtered and concentrated to use the concentrated solution as a material, or powder dried to use as a powder. Alternatively, the extracts can be extracted with water or alcohol after grinding each material. Extraction by steam distillation can also produce desirable results.
본 발명의 숙취해소용 조성물은 후술하는 시험예로부터 확인할 수 있는 바와 같이 건강 기능성 식품 및 숙취의 해소, 예방 및 개선을 위한 약제학적 제제로 이용될 수 있다. 상기 건강기능성 식품은 일반 건강식품 또는 다이어트나 피로회복, 숙취해소용 등의 다목적 기능을 갖는 기능성 건강 식품으로도 이용될 수 있다.Hangover composition of the present invention can be used as a pharmaceutical preparation for the elimination, prevention and improvement of health functional food and hangover as can be seen from the test examples described below. The health functional food may also be used as a general health food or a functional health food having a multipurpose function such as diet or fatigue, hangover relief.
본 발명에 따른 의약 및 기능성 식품 조성물은 당해 분야에서의 통상적인 방법에 따라, 예를 들면 분말, 과립, 환, 정제, 캡슐, 액상 또는 음료 형태를 포함하는 제형으로 제공할 수 있다.The pharmaceutical and functional food compositions according to the invention may be provided in formulations comprising, for example, powders, granules, pills, tablets, capsules, liquids or beverages according to conventional methods in the art.
본 발명의 제약 또는 식품 조성물의 섭취량은 그 제제 형태, 투여 방법, 사용 목적 및 이것에 적용되는 개체의 연령, 체중, 증상에 따라서 적절히 설정되고, 일정하지 않지만 일반적으로는 제제 중에 함유되는 유효성분의 양은 성인 1일당, 예컨대 25 mg～5,000 ㎎/㎏이다. 물론 복용량은, 각종 조건에 의해서 변동하기 때 문에, 상기 섭취량보다 적은 양으로 충분한 경우도 있고, 또는 범위를 초과하여 필요한 경우도 있다.The intake amount of the pharmaceutical or food composition of the present invention is appropriately set according to the form of the preparation, the method of administration, the purpose of use, and the age, weight, and symptoms of the individual to which it is applied. The amount is, for example, 25 mg to 5,000 mg / kg per adult. Of course, since the dose varies depending on various conditions, an amount smaller than the intake amount may be sufficient, or it may be necessary beyond the range.
본 발명의 조성물이 약제학적 조성물로 제조되는 경우에는 약제학적으로 허용되는 담체를 추가적으로 포함한다. 약제학적으로 허용되는 담체는 제제시에 통상적으로 이용되는 것으로서, 탄수화물류 화합물(예: 락토오스, 아밀로스, 덱스트로스, 수크로오스, 솔비톨, 만니톨, 전분, 셀룰로오스 등), 아카시아 고무, 인산 칼슘, 알기네이트, 젤라틴, 규산 칼슘, 미세결정성 셀룰로오스, 폴리비닐피롤리돈, 셀룰로오스, 물, 시럽, 염 용액, 알코올, 아라비아 고무, 식물성 기름(예: 옥수수 기름, 목화 종자유, 두유, 올리브유, 코코넛유), 폴리에틸렌 글리콜, 메틸 셀룰로오스, 메틸히드록시 벤조에이트, 프로필히드록시 벤조에이트, 활석, 스테아르산 마그네슘 및 미네랄 오일 등을 포함하나, 이에 한정되는 것은 아니다. 본 발명의 약제학적 조성물은 상기 성분들 이외에 윤활제, 습윤제, 감미제, 향미제, 유화제, 현탁제, 보존제 등을 추가로 포함하나, 이에 한정되는 것은 아니다.When the composition of the present invention is prepared as a pharmaceutical composition, it further includes a pharmaceutically acceptable carrier. Pharmaceutically acceptable carriers are those commonly used in the preparation of carbohydrates (e.g., lactose, amylose, dextrose, sucrose, sorbitol, mannitol, starch, cellulose, etc.), acacia rubber, calcium phosphate, alginate, Gelatin, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, water, syrup, salt solution, alcohol, gum arabic, vegetable oils (e.g. corn oil, cotton seed oil, soy milk, olive oil, coconut oil), polyethylene Glycol, methyl cellulose, methylhydroxy benzoate, propylhydroxy benzoate, talc, magnesium stearate and mineral oil, and the like. The pharmaceutical composition of the present invention further includes, but is not limited to, lubricants, wetting agents, sweeteners, flavoring agents, emulsifiers, suspending agents, preservatives, and the like, in addition to the above components.
또한, 본 발명의 조성물이 기능성 식품(건강기능식품 및 일반 식품) 조성물로 제조되는 경우에는 식품에 통상적으로 첨가되는 성분을 포함할 수 있으며, 예를 들어, 단백질, 탄수화물, 지방, 감미료를 포함한 식품첨가물을 포함한다. In addition, when the composition of the present invention is prepared as a functional food (health functional food and general food) composition may include ingredients that are commonly added to food, for example, food, including protein, carbohydrates, fat, sweeteners Contains additives.
본 발명에 따른 숙취해소용 의약 및 식품 조성물은 더욱 바람직한 실시형태에 있어서, 호박산 10~48 중량%, 푸마르산 5~27 중량%, L-글루타민산 또는 L-글루타민산나트륨 1~19 중량%, 비타민 B1, 비타민 B2, 비타민 B6 또는 이들의 혼합물 중에서 선택된 비타민 B 0.05~6 중량%, L-주석산 0.5~4 중량%, 타우린 4~20 중량%, L-아르기닌 0.5~4 중량%, L-카르니틴 0.5~4 중량%, 글리신 1~6 중량%, 및 오미자 추출분말(고형분) 0.5~4 중량%을 포함한다.
상기 조성물은 추가로 본 발명의 조성물의 전체 중량을 기준으로 액상과당 0.01~20 중량%, 벌꿀 0.01~2 중량%, 황금 추출액 0.01~2 중량%, 유카 추출액 0.01~2 중량%, 배 추출액 0.01~2 중량%, 대추 추출액 0.01~2 중량%, 갈근 추출액 0.01~2 중량%, 감초 추출액 0.01~2 중량%, 및 매실 추출액 0.01~2 중량%로 이루어진 군 중에서 선택된 하나 이상의 성분을 포함할 수도 있다. Hangover medicament and food composition according to the present invention in a more preferred embodiment, 10 to 48% by weight of succinic acid, 5 to 27% by weight of fumaric acid, 1 to 19% by weight of L- glutamic acid or L- glutamate, vitamin B 1 Selected from vitamin B 2 , vitamin B 6, or a mixture thereof, 0.05 to 6% by weight of vitamin B, 0.5 to 4% by weight of L-tartrate, 4 to 20% by weight of taurine, 0.5 to 4% by weight of L-arginine, L-carnitine 0.5-4% by weight, glycine 1-6% by weight, and Schizandra chinensis extract powder (solid content).
The composition is further based on the total weight of the composition of the present invention 0.01 to 20% by weight of liquid fructose, 0.01 to 2% by weight of honey, 0.01 to 2% by weight of golden extract, 0.01 to 2% by weight of yucca extract, 0.01 to 0.01% of pear extract It may include one or more components selected from the group consisting of 2% by weight, jujube extract 0.01 ~ 2% by weight, root extract extract 0.01 ~ 2% by weight, licorice extract 0.01 ~ 2% by weight, and plum extract 0.01 ~ 2% by weight.
삭제delete
삭제delete
추가로 상기 조성물에 향을 부여하기 위하여 향미료를 첨가할 수 있으며, 예를 들면 쌍화차향, 허브향, 홍삼향 및 과일향 등을 사용할 수 있다.In addition, flavoring may be added to impart flavor to the composition, and for example, ssanghwa tea, herbal flavor, red ginseng flavor and fruit flavor may be used.
음료의 경우, 본 발명에 따른 숙취해소용 조성물을 정제수로 5~200배 희석하여 제조할 수 있다. 따라서, 본 발명은 구체적인 실시형태에 있어서, 호박산 10~48 중량%, 푸마르산 5~27 중량%, L-글루타민산 또는 L-글루타민산나트륨 1~19 중량%, 비타민 B 0.05~6 중량%, L-주석산 0.5~4 중량%, 타우린 4~20 중량%, L-아르기닌 0.5~4 중량%, L-카르니틴 0.5~4 중량%, 글리신 1~6 중량%, 및 오미자 추출분말(고형분) 0.5~4 중량%을 포함하는 조성물을 5~200배 희석하여 제조된 것인 음주로 인한 숙취 예방 및 숙취해소용 음료를 제공한다.In the case of beverages, the composition for releasing hangovers according to the present invention may be prepared by diluting 5-200 times with purified water. Thus, in a specific embodiment of the present invention, 10 to 48% by weight of succinic acid, 5 to 27% by weight of fumaric acid, 1 to 19% by weight of L-glutamic acid or L-glutamic acid, 0.05 to 6% by weight of vitamin B, L-tartrate 0.5-4% by weight, 4-20% by weight of taurine, 0.5-4% by weight of L-arginine, 0.5-4% by weight of L-carnitine, 1-6% by weight of glycine, and 0.5-4% by weight of Schizandra chinensis powder (solid) It provides a drink for preventing hangover and hangover caused by drinking that is prepared by diluting a composition containing 5 to 200 times.
<실시예><Examples>
이하, 본 발명에 따른 숙취해소용 조성물을 바람직한 실시예를 통해 설명하고자 한다. 이 실시예는 오로지 본 발명을 보다 구체적으로 설명하기 위한 것으로서, 본 발명의 요지에 따라 본 발명의 범위가 이 실시예에 의해 제한되지 않는다는 것은 본 발명이 속하는 기술 분야에서 통상의 지식을 가진 자에게 있어서 자명할 것이다. Hereinafter, the hangover composition according to the present invention will be described through preferred embodiments. This embodiment is only for illustrating the present invention in more detail, and the scope of the present invention is not limited by this embodiment according to the gist of the present invention to those skilled in the art. Will be self-evident.
실시예 1: 식물 추출물의 제조Example 1: Preparation of Plant Extract
각각의 오미자, 황금, 유카, 배, 대추, 갈근, 감초, 매실 500g을 잘 세척한 후, 정제수 2 리터를 가하여 고압멸균솥에서 3 시간 동안 추출하였다. 이어서 여과하여 농축한 액을 분말화하여 각각의 분말 50g을 얻어 이를 후속 실시예에 사용하였다.500 g of each Schizandra chinensis, golden, yucca, pear, jujube, brown root, licorice and plums were washed well, and then, 2 liters of purified water was added and extracted in a autoclave for 3 hours. The filtrate was then concentrated to powder to give 50 g of each powder which was used in the subsequent examples.
실시예 2: 기능성 식품 조성물의 제조Example 2: Preparation of Functional Food Composition
다음의 표 1에 나타낸 성분을 혼합하여 기능성 정제 형태의 식품 조성물을 제조하였다.The ingredients shown in Table 1 were mixed to prepare a food composition in the form of a functional tablet.
상기 각 실시예의 성분과 히드록시 프로필메틸 셀룰로오스 8g, 결정셀룰로오스 43.44g, 스테아린산 마그네슘 8g을 혼합하여 정제로 타정하였다. 본 실시예에서는 식물 추출물로서 오미자 추출분말을 사용하였으나, 본 발명은 이에 제한되지 않고, 상기한 각각의 추출물을 필요에 따라서 첨가할 수 있음은 자명하다.8 g of hydroxypropylmethyl cellulose, 43.44 g of crystalline cellulose, and 8 g of magnesium stearate were mixed and compressed into tablets. In the present embodiment, the Schizandra chinensis extract powder was used as the plant extract, but the present invention is not limited thereto, and it is apparent that each of the extracts may be added as necessary.
실시예 3~7: 정제의 제조Examples 3-7: Preparation of Tablets
다음의 표 2에 나타낸 성분을 혼합하여 기능성 정제 형태의 식품 조성물을 제조하였다.Food ingredients in the form of functional tablets were prepared by mixing the ingredients shown in Table 2 below.
상기 각 실시예의 성분과 히드록시프로필메틸 셀룰로오스 8g, 결정셀룰로오스 43.44g, 스테아린산 마그네슘 8g을 혼합하여 정제로 타정하였다.8 g of hydroxypropylmethyl cellulose, 43.44 g of crystalline cellulose, and 8 g of magnesium stearate were mixed and compressed into tablets.
실시예 8: 캡슐의 제조Example 8: Preparation of Capsules
1,000 캡슐을 기준으로 호박산 108 g, 푸마르산 60 g, L-글루타민산나트륨 42 g, L-주석산 7.5 g, 비타민 B1 6 g, 비타민 B2 3 g 및 비타민 B6 3 g을 균질하게 혼합하고 이를 통상의 방식에 의하여 캡슐(1,000 캡슐 기준)을 제조하였다.On a 1,000 capsule basis, homogeneously mix 108 g of succinic acid, 60 g of fumaric acid, 42 g of sodium L-glutamate, 7.5 g of L-tartrate, 6 g of Vitamin B1, 3 g of Vitamin B2 and 3 g of Vitamin B6 and mix it in a conventional manner. Capsules (based on 1,000 capsules) were prepared.
실시예 9: 캡슐의 제조Example 9 Preparation of Capsules
1,000 캡슐을 기준으로 호박산 108g, 푸마르산 60g, L-글루타민산나트륨 42g, L-주석산 7.5g, 비타민 B1 6g, 비타민 B2 3g 및 비타민 B6 3g, 글리신 13.5g, 황납 13.5g, 대두레시틴 9g, L-아르기닌 7.5g, L-카르니틴 1.25g, 오미자추출분말 6g을 혼합하고 이를 통상의 방식에 의하여 캡슐을 제조하였다.Based on 1,000 capsules, 108 g of succinic acid, 60 g of fumaric acid, 42 g of sodium L-glutamate, 7.5 g of L-tartrate, 6 g of vitamin B1, 3 g of vitamin B2 and 3 g of vitamin B6, 13.5 g of glycine, 13.5 g of soy lecithin, 9 g of soy lecithin, L-arginine 7.5g, L-carnitine 1.25g, 6g of Schisandra chinensis powder was mixed and it was prepared capsules in a conventional manner.
실시예 10 : 음료의 제조Example 10 Preparation of Beverages
상기 실시예 3에서 제조한 조성물 6.4668g을 혼합한 후, 나머지는 정제수로 첨가한 후 음료수 1ℓ를 제조한 다음, 미량의 액상과당, 벌꿀과 향료를 첨가하여 저온살균하여 본 발명의 조성물로 제조하였다. 결과적으로 본 발명 음료수는 종래의 음료수 제품과 입안 감촉, 맛 그리고 종합평가 면에서 양호한 반응을 얻었다.After mixing 6.4668 g of the composition prepared in Example 3, the rest was added to purified water, and then 1 liter of beverage was prepared, followed by pasteurization by adding a small amount of liquid fructose, honey and flavoring to prepare a composition of the present invention. . As a result, the beverage of the present invention obtained a favorable response from the conventional beverage product in terms of mouth feel, taste and comprehensive evaluation.
실험예 1 : 혈중 알코올 농도 감소 효과 측정Experimental Example 1: Measurement of the effect of reducing blood alcohol concentration
본 발명에 따른 조성물의 숙취 예방 및 개선 효능을 확인하기 위해 20에서 50대의 남녀 20명을 무작위로 선발하여 각각 실험군과 대조군으로 나누고 이들을 대상으로 임상실험을 실시하였다. 실험을 시작하기 전 일주일간은 금주하도록 하였다. 알코올 음료를 섭취하기 30분 전 실험군은 상기 표 1의 조성물 800mg을 섭취하도록 하고, 대조군에는 동일한 부피의 위약을 섭취하도록 하였다. 실험대상자들은 각각 30분 후 20%의 알코올 음료 200㎖를 15분간 마시게 하였다. 섭취가 끝난 후 0, 30분, 1, 2, 3시간 경과한 시점에서 혈액을 채취하여 Enzymatic bioanalysis UV-method(F-Kit Roche, Cat. No.0176290)로 사용한 Kit의 조작법에 의해 혈중 알코올 농도를 측정하여, 그 결과를 표 3에 나타내었다.In order to confirm the effect of preventing and improving hangover of the composition according to the present invention, 20 men and women in their 50s were randomly selected and divided into experimental groups and control groups, respectively, and clinical trials were performed on them. This week was a week before the experiment. Thirty minutes before ingesting the alcoholic beverage, the experimental group was to take 800 mg of the composition of Table 1, and the control group to take the same volume of placebo. Subjects were allowed to drink 200 ml of 20% alcoholic beverages for 15 minutes after 30 minutes each. Blood alcohol concentration was measured by kit operation using Enzymatic bioanalysis UV-method (F-Kit Roche, Cat.No.0176290) at 0, 30 minutes, 1, 2, 3 hours after ingestion. Was measured, and the results are shown in Table 3.
실험예 2 : 혈중 아세트알데히드 농도 감소 효과 측정Experimental Example 2: Determination of the Effect of Acetaldehyde Concentration in Blood
상기 실험예 1의 실험대상자에 대하여 혈중 아세트알데히드 농도를 Enzymatic bioanalysis UV-method(F-Kit Roche, Cat. No.0668613)로 사용한 Kit의 조작법에 의해 혈중 아세트알데히드 농도를 측정하였다. 측정한 결과를 평균화하였으며, 그 결과를 표 4에 나타내었다.Blood acetaldehyde concentration was measured by the kit operation using Enzymatic bioanalysis UV-method (F-Kit Roche, Cat. No.0668613). The measured results were averaged and the results are shown in Table 4.
표 3 및 4에 나타낸 바와 같이, 본 발명의 조성물은 임상실험 결과 섭취가 끝난 후 0, 30분, 1, 2, 3 시간에 혈중 알코올 농도 감소율(%)이 2.79, 12.73, 39.54, 37.45, 23.12로 감소하였고, 혈중 아세트알데히드 농도가 28.00, 3.33, 52.17, 50.00, 54.84로 감소하는 것을 확인하였으며, 이는 도 1에서 나타내었다. As shown in Tables 3 and 4, the composition of the present invention showed that the percentage of decrease in blood alcohol concentration (%) was 2.79, 12.73, 39.54, 37.45, 23.12 at 0, 30 minutes, 1, 2, and 3 hours after the end of the clinical trial. It was confirmed that the concentration of acetaldehyde in blood decreased to 28.00, 3.33, 52.17, 50.00, 54.84, which is shown in FIG.
따라서, 기능성 식품 조성물이 뚜렷한 숙취해소 효과를 나타냄을 확인하였다.Therefore, it was confirmed that the functional food composition exhibits a clear hangover effect.
실험예 3 : 간 기능 검사 (SGPT(ALT), SGOT(AST)Experimental Example 3 Liver Function Test (SGPT (ALT), SGOT (AST)
상기 실험예 1의 실험군의 대상자에 한하여 알코올 음료 복용 전 최초 채혈시와 마지막 채혈시 혈액의 SGPT(ALT), SGOT(AST) 를 측정하였다. SGPT (ALT), SGOT (AST) of blood at the time of the first blood collection and the last blood collection before the alcoholic beverage was measured only for the subjects of the experimental group of Experimental Example 1.
측정한 결과를 표 5에 나타내었으며, SGPT(ALT), SGOT(AST)가 유의적으로 감소하는 것을 확인하였다. The measurement results are shown in Table 5, and it was confirmed that SGPT (ALT) and SGOT (AST) were significantly decreased.
최초 채혈시Before taking alcoholic drinks
At first blood collection
마지막 채혈시After taking alcoholic beverages
At the last blood collection
실험예 4 : 피로 회복 능력 평가Experimental Example 4: Evaluation of fatigue recovery ability
피로 회복 능력을 평가하기 위해 20에서 50대의 남녀 20명을 무작위로 선별하여 각각 실험군과 대조군으로 나누고, 운동검사 시작 1시간 전에 표 1에 나타낸 조성물을 각각 투여하였다. 이들을 대상으로 혈액 변인인 혈중 젖산 농도를 안정시, 운동 직 후, 회복기 3분, 10분, 20분에 측정하여 그 결과를 표 6에 나타내었다.To evaluate fatigue recovery ability, 20 men and women in their 20s and 50s were randomly selected and divided into experimental and control groups, respectively, and the compositions shown in Table 1 were administered 1 hour before the start of the exercise test. The blood lactate concentration, a blood variable, was measured at rest, 3 minutes, 10 minutes and 20 minutes immediately after exercise, and the results are shown in Table 6.
Variable
group
Time
At rest
Right after exercise
Lactate(mmol/L)
Lactate (mmol / L)
Control group
상기 표 6의 결과에서 알 수 있는 바와 같이, 본 발명의 조성물은 임상실험 결과 혈중 젖산 농도를 유의적으로 감소시켜, 피로회복에 영향을 미침을 확인하였다. As can be seen from the results of Table 6, the composition of the present invention was confirmed to significantly reduce blood lactate concentration in clinical trials, affecting fatigue recovery.
본 발명의 숙취해소 조성물은 임상실험 결과 혈중 알코올 농도 및 아세트알데히드 농도를 격감시키는 것으로 나타나 우수한 숙취 증상의 예방 및 숙취해소의 효능을 발휘할 뿐만 아니라, 음주로 인해 유발되는 간수치 증대를 억제하므로 간을 해독, 보호하는 효과도 갖는다. 또한, 상기 숙취해소의 효과와 더불어 젖산의 분비를 감소시키므로 피로 회복의 효과도 가지므로, 이를 기능성 식품 및 의약 제형으로 제공될 수 있다.The hangover relief composition of the present invention has been shown to reduce blood alcohol and acetaldehyde concentration in clinical trials, and not only exerts the effect of preventing hangover symptoms and relieving hangover, but also inhibits the increase in liver values caused by drinking, thus detoxifying the liver. It also has a protective effect. In addition, since the effect of relieving hangover and reducing the secretion of lactic acid also has the effect of fatigue recovery, it can be provided as a functional food and pharmaceutical formulation.
도 1은 본 발명에 따른 조성물의 혈중 알코올 농도와 혈중 아세트알데히드 농도 시험 결과를 나타내는 그라프도.1 is a graph showing blood alcohol concentration and blood acetaldehyde concentration test results of the composition according to the present invention.
Claims (8)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20080016607 | 2008-02-25 | ||
| KR1020080016607 | 2008-02-25 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20090091653A KR20090091653A (en) | 2009-08-28 |
| KR101177888B1 true KR101177888B1 (en) | 2012-08-28 |
Family
ID=41209008
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020090011474A KR101177888B1 (en) | 2008-02-25 | 2009-02-12 | Composition for Relieving and Preventing Hangover |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR101177888B1 (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015008101A1 (en) * | 2013-07-15 | 2015-01-22 | Schaumlöffel Rolf A | Composition of a drink for enhanced reduction of blood alcohol level |
| CN103829245B (en) * | 2014-03-13 | 2016-02-17 | 太原纠偏食品开发有限公司 | A kind of rectification food downgrading altitude sickness and preparation method thereof |
| CN104522571A (en) * | 2014-12-05 | 2015-04-22 | 安徽金龙山葛业有限公司 | Technology for making wild radix puerariae into full powder of ultramicro radix puerariae powder |
| KR101654737B1 (en) | 2016-01-05 | 2016-09-06 | 임창혁 | A composition having extracts of trifoliate orange for release of hangover and manufacturing method thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2000128784A (en) * | 1998-10-20 | 2000-05-09 | Kuressendo Corporation:Kk | Hangover symptom |
| JP2005154411A (en) * | 2003-11-27 | 2005-06-16 | Sarusu Biotech Corp | Composition for preventing/removing hangover |
-
2009
- 2009-02-12 KR KR1020090011474A patent/KR101177888B1/en not_active IP Right Cessation
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2000128784A (en) * | 1998-10-20 | 2000-05-09 | Kuressendo Corporation:Kk | Hangover symptom |
| JP2005154411A (en) * | 2003-11-27 | 2005-06-16 | Sarusu Biotech Corp | Composition for preventing/removing hangover |
Also Published As
| Publication number | Publication date |
|---|---|
| KR20090091653A (en) | 2009-08-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR100704523B1 (en) | Composition comprising theanine | |
| JP5650629B2 (en) | Lipase activity inhibitor, tea extract containing high-molecular polyphenol fraction, and method for producing the same | |
| KR101396458B1 (en) | A food or drink composition comprising fermented eastern prickly pear | |
| KR20160144791A (en) | Composition for relieving menopausal symptom | |
| JP3859988B2 (en) | Antihypertensive agent | |
| JPH08225453A (en) | Lipoprotein (a) depressor, cholesterol depressor and medicine containing the same | |
| KR101177888B1 (en) | Composition for Relieving and Preventing Hangover | |
| KR101093998B1 (en) | Functional composition for the prevention of hangover and improving liver function | |
| JP2015502954A (en) | A composition for preventing or treating dyslipidemia, comprising an aqueous extract of Aguitake as an active ingredient | |
| JP6821163B2 (en) | Composition for prevention or treatment of diseases caused by caffeine addiction containing Goshuyu extract or evodiamine as an active ingredient | |
| KR100638491B1 (en) | Compounds for relief of alcoholic hangover and drug containing the compounds | |
| KR100392876B1 (en) | A drink for eliminating a hangover and a method for producing the same | |
| KR101210748B1 (en) | Composition comprising the extract of Acanthopanax sessiliflorus and green tea for treating or alleviating hangover syndrome | |
| KR102235563B1 (en) | Composition for fatigue recovery and sexual function improvement containing high content of arginine | |
| CN113749203A (en) | Beverage with weight reducing effect and preparation method thereof | |
| KR20080033717A (en) | Health assistance food composition using honey and crude drugs and the making method | |
| JP2003171297A (en) | Blood bilirubin concentration depressant and medicine for treatment/prevention of jaundice | |
| JP2005139135A (en) | Prophylactic and ameliorating agent of menopausal disorder | |
| KR101528557B1 (en) | A pharmaceutical composition comprising fermented Eastern prickly pear | |
| CN112691150A (en) | Composition and preparation method and application thereof | |
| JP4125011B2 (en) | Excess iron-induced liver injury prevention / treatment agent and excess iron-induced liver injury prevention / treatment | |
| AU2021100330A4 (en) | A Kind Of Gamma-Aminobutyric Acid Composition Rich In Botanical Herbs And Its Preparation Method | |
| CN108720013A (en) | The formula and processing technology of the health food of one group of Soboring-up liver-protecting being made of fructose and tea extract | |
| KR20130065127A (en) | Composition comprising alcohol extracts from oligoporus tephroleucus for treating or preventing hyperlipidemia | |
| KR20130065086A (en) | Composition comprsing alcohol extracts from albatrellus dispansus for treating or preventing hyperlipidemia |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| E902 | Notification of reason for refusal | ||
| AMND | Amendment | ||
| E902 | Notification of reason for refusal | ||
| E601 | Decision to refuse application | ||
| AMND | Amendment | ||
| J201 | Request for trial against refusal decision | ||
| B701 | Decision to grant | ||
| GRNT | Written decision to grant | ||
| FPAY | Annual fee payment |
Payment date: 20150822 Year of fee payment: 4 |
|
| FPAY | Annual fee payment |
Payment date: 20160819 Year of fee payment: 5 |
|
| FPAY | Annual fee payment |
Payment date: 20170808 Year of fee payment: 6 |
|
| LAPS | Lapse due to unpaid annual fee |